Anti-PCSK۹ monoclonal antibody attenuates high-fat diet and zymosan-induced vascular inflammation in C۵۷BL/۶ mice by modulating TLR۲/NF-ƙB signaling pathway

  • سال انتشار: 1401
  • محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 25، شماره: 5
  • کد COI اختصاصی: JR_IJBMS-25-5_005
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 207
دانلود فایل این مقاله

نویسندگان

Priyanka Arya

Department of Pharmacology, School of Pharmaceutical Education & Research (SPER), Jamia Hamdard, New Delhi - ۱۱۰۰۶۲, India

Uma Bhandari

Department of Pharmacology, School of Pharmaceutical Education & Research (SPER), Jamia Hamdard, New Delhi - ۱۱۰۰۶۲, India

Kalicharan Sharma

Department of Pharmaceutical Chemistry, SPS, DPSRU, New Delhi-۱۱۰۰۱۷

Priyanka Bansal

Department of Pharmacology, School of Pharmaceutical Education & Research (SPER), Jamia Hamdard, New Delhi - ۱۱۰۰۶۲, India

چکیده

Objective(s): Excess intake of a high-fatty diet (HFD) together with zymosan administration mediates vasculitis response which leads to impaired serum lipid levels and causes arterial stiffness. In the development of new cholesterol-lowering medications, PCSK۹ inhibitor (proprotein convertase subtilisin/kexin type ۹) is an emerging therapeutic. The goal of the present study was to see whether anti-PCSK۹ mAb۱ might prevent vasculitis in C۵۷BL/۶ mice by blocking TLR۲/NF-B activation in HFD and Zymosan-induced vasculitis. Materials and Methods: Protein-protein molecular docking was performed to validate the binding affinity of anti-PCSK۹ mAb۱ against TLR۲. Under the experimental study, mice were randomly allocated to the following groups: Group I: standard mice diet (۳۰ days) + Zymosan vehicle (sterile PBS solution of ۵mg/ml on ۸th day); Group II: HFD (۳۰ days) + Zymosan ( single IP dose ۸۰ mg/kg on day ۸th); Group III: HFD+Zymosan + anti-PCSK۹ mAb۱ (۶ mg/kg, s.c. on ۱۰th and ۲۰th days); Group IV: HFD+Zymosan+anti-PCSK۹ mAb۱ (۱۰ mg/kg, s.c. on ۱۰th and ۲۰th days).Results: In comparison with the low dose of anti-PCSK۹ mAb۱ (۶ mg/kg), the high dose of anti-PCSK۹ mAb۱ (۱۰ mg/kg) together with HFD and Zymosan inhibited vasculitis more effectively by decreasing aortic TLR۲ and NF-B levels, reducing serum TNF- and IL-۶, and up-regulating liver LDLR levels, which down-regulated serum LDL-C and improved serum lipids levels. Histopathological studies showed that anti-PCSK۹ mAb۱ treatment reduced plaque accumulation in the aorta of mice.Conclusion: These findings indicate that anti-PCSK۹ mAb۱ has therapeutic potential in reducing HFD and Zymosan-induced vascular inflammation.  

کلیدواژه ها

Anti-PCSK۹ antibody, High-fat diet, Inflammation, Toll-Like Receptor, Zymosan

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.